-
Sector Analysis
Uveitis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 7MM (US, 5EU, Japan) and provides an Excel-based forecast model for the uveitis market through 2033. There will be an overall increase in the diagnosed prevalent cases of uveitis in the 7MM across the forecast period. Across the 7MM, the mainstay treatment for uveitis involves the use of anti-inflammatory therapies. Significant clinical unmet needs remain in the uveitis market. The late-stage uveitis pipeline consists of six agents. The uveitis market in the 7MM was valued at...
-
Product Insights
Glaucoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Glaucoma - Global Clinical Trials Review, 2025" provides an overview of Glaucoma Clinical trials scenario. This report provides top line data relating to the clinical trials on Glaucoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Endometriosis in 68-Markets: Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2034
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Endometriosis market. Across the 68 markets, sales in the endometriosis market were $1.5 billion in 2024, growing to $4.6 billion in 2034. The seven major markets (US, France, Germany, Italy, Spain, UK, and Japan) represent approximately 37.5% and 45.9% in 68-market sales in 2024 and 2034, respectively.
-
Sector Analysis
GLP-1R Agonists - Label Extensions/Drug Repurposing - Market Overview, Trends, Pricing, Pipeline Analysis, Future Players, Opportunities and Challenges
This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity. The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties. GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets. Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.
-
Sector Analysis
Glaucoma in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2032
Glaucoma Market Report Overview The glaucoma market size across the 68M was $3.1 billion in 2023. The “Glaucoma in 68 Markets” research report covers the 68 geographical markets and provides an Excel-based forecast model for the market through 2033. Glaucoma Market Outlook, 2023-2033 ($ Billion) Buy the Full Report for More Insights on the Glaucoma Market Report Forecast Download a Free Report Sample The Glaucoma market report contains patient-based forecast sales data for the seven major markets (7MM: US, France,...
-
Sector Analysis
Glaucoma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
Glaucoma Market Report Overview The Glaucoma market sales across the 7MM was $2.1 billion in 2023. The sales of glaucoma therapeutics across the 7MM will grow at a compound annual growth rate (CAGR) of more than 2% between 2023 and 2033. Factors such as the surge in the prevalence of glaucoma due to the ageing population and the launch of new products addressing the unmet needs in glaucoma treatment will drive growth in the glaucoma market across the 7MM. Glaucoma...
-
Product Insights
Macular Edema Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Macular Edema Clinical Trial Report Overview A total of 1628 macular edema clinical trials were conducted as of November 2024. The macular edema clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions · Asia-Pacific · North America · ...
-
Sector Analysis
Glaucoma Epidemiology Analysis and Forecast to 2033
Glaucoma Report Overview In the 7MM, there were 4,190,943 diagnosed incident cases of primary open-angle glaucoma (POAG) excluding NTG in 2023. The diagnosed incident cases of glaucoma will register an AGR of more than 1% during 2023-2033. Glaucoma is a group of progressive neurodegenerative eye diseases caused by damage to the optic nerve. Glaucoma has a major effect on quality of life and is the primary cause of blindness and vision loss worldwide. It is categorized as primary open-angle glaucoma...
-
Thematic Analysis
Digital Marketing Trends in Age-related Macular Degeneration
Digital Marketing Trends in Age-related Macular Degeneration Report Overview Genentech’s Vabysmo.com achieved the highest total traffic across branded age-related macular degeneration (AMD) patient sites in the US, with over two million visits from June 2023 to May 2024. This was followed by Bayer’s Eylea.us. Overall, the highest proportion of traffic to branded AMD websites originated from direct sources followed by organic. No traffic was detected in the five major European markets (5EU: France, Germany, Italy, Spain, the UK, and Canada)...
-
Sector Analysis
Presbyopia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Presbyopia therapeutics. • In 2024, more than 1.65 billion diagnosed prevalent cases of Presbyopia are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for Presbyopia. • Currently, the market space for Presbyopia holds only two approved products. • R&D activities for presbyopia are moderate with 19 molecules in pipeline out of which five drugs are in Phase III. • The US is emerging as...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.